What is HC Wainwright's Forecast for PVLA FY2027 Earnings?

Key Points

• HC Wainwright cut its FY2027 EPS forecast for Palvella Therapeutics to a loss of $13.52 per share from a previous estimate of $7.43, while maintaining a Buy rating and $246 price target.
• The analyst projects continued losses of $10.40 per share in FY2028 and $4.84 in FY2029, followed by positive EPS of $5.82 in FY2030. Palvella’s current-year consensus estimate is a loss of $6.40 per share.
• Palvella recently missed quarterly earnings expectations, reporting a $1.52-per-share loss versus the $1.17 consensus estimate; despite the setback, analysts maintain a Moderate Buy consensus with a $207.43 average price target.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Research analysts at HC Wainwright dropped their FY2027 earnings per share estimates for shares of Palvella Therapeutics in a research note issued on Monday, October 12th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($13.52) per share for the year, down from their previous estimate of ($7.43). HC Wainwright has a "Buy" rating and a $246.00 price target on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($6.40) per share. HC Wainwright also issued estimates for Palvella Therapeutics' FY2028 earnings at ($10.40) EPS, FY2029 earnings at ($4.84) EPS and FY2030 earnings at $5.82 EPS.

Several other research analysts also recently weighed in on PVLA. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Chardan Capital initiated coverage on shares of Palvella Therapeutics in a research note on Monday, September 21st. They set a "buy" rating and a $240.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Finally, Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $207.43.

Palvella Therapeutics Trading Down 4.4%

PVLA opened at $128.51 on Wednesday. The firm's 50 day moving average is $147.39 and its 200-day moving average is $134.28. Palvella Therapeutics has a 52-week low of $68.96 and a 52-week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35).

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $152.24, for a total value of $654,936.48. Following the transaction, the chief operating officer directly owned 2,154 shares of the company's stock, valued at $327,924.96. This represents a 66.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George M. Jenkins sold 1,777 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $150.14, for a total value of $266,798.78. Following the transaction, the director owned 160,116 shares of the company's stock, valued at approximately $24,039,816.24. This trade represents a 1.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,417 shares of company stock worth $5,526,138 in the last three months. 17.20% of the stock is owned by insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Palvella Therapeutics during the second quarter worth about $35,000. Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the second quarter worth about $69,000. Quantbot Technologies LP acquired a new position in Palvella Therapeutics in the second quarter worth about $71,000. Finally, State of Wyoming acquired a new position in Palvella Therapeutics in the second quarter worth about $134,000. Institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company's work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella's lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.